Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata`s Bacteriophage Development Programs MARINA DEL REY, Calif. and BRISBANE, Calif., Jan. 28, 2020/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (`Armata`), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, and Innoviva, Inc. (NASDAQ: INVA) (`Innoviva`), a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited, today announced that they have entered into a securities purchase agreement pursuant to which Innoviva will purchase, upon satisfaction of...
|
